Ketan Acharya

Sir, congratulations on excellent quarter with commercial molecules driving growth. Another capacity expansion announced today and EBITDA margins expanding significantly. Should investors view this as a beginning of a structurally higher earning phase for Neuland rather than just a favorable product mix quarter?

And to add to that, sir, is this going to be due to higher utilization of existing commercial molecules or new commercial molecule launches would support this? And just the last thing, are we looking at any stock split or bonus because that question has been asked in several con calls, but never answered.

It's glad to be a 10-year-old investor in your company.